Cognitive behavior therapy to facilitate benzodiazepine discontinuation among hypnotic-dependent patients with insomnia

Morin, Charles M.; Colecchi, Cheryl; Ling, William; Sood, Rakesh

doi:10.1016/s0005-7894(05)80042-5

Cited by 44 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24,25 Psychological treatments targeting insomnia have also been successful in significantly reducing hypnotic intake and encouraging total withdrawal. 26 However, despite the potential for improved insomnia management and reduced hypnotic drug dependence through psychological treatments, such approaches are rarely deployed in non-specialised primary care settings. Emphasising this point, a recent review of psychological treatments for insomnia concluded "… research is needed to examine the effectiveness of treatment when it is implemented in clinical settings (primary care, family practice), by non-sleep specialists, and with insomnia patients presenting medical or psychiatric comorbidity."…”

Section: Psychological Treatments For Insomniamentioning

confidence: 99%

Psychological treatment for insomnia in the regulation of long-term hypnotic drug use

Morgan

Dixon²,

Mathers³

et al. 2004

Health Technol Assess

196

117

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure was replaced in 2000 by three new pan...

show abstract

Section: Psychological Treatments For Insomniamentioning

confidence: 99%

Psychological treatment for insomnia in the regulation of long-term hypnotic drug use

Morgan

Dixon²,

Mathers³

et al. 2004

Health Technol Assess

196

117

View full text Add to dashboard Cite

show abstract

“…En résumé, les résultats de la présente étude appuient les écrits scientifiques qui démontrent que la thérapie comportementale et cognitive s'avère utile dans le contexte du sevrage des benzodiazépines (Baillargeon et al, 1998 ;Morin et al, 1995 ;Otto et al, 1993 ;Spiegel et al, 1994). Malgré ces premiers résultats encourageants, d'autres études s'avèrent nécessaires afin de répondre aux interrogations soulevées.…”

Section: Discussionunclassified

“…Fait à noter, les patients qui réus-sissent à cesser de prendre leur benzodiazépine après une utilisation prolongée ressentent paradoxalement moins d'anxiété et moins de symptômes dépressifs (Miller, 1995 ;Rickels et al, 1999). La thérapie comportementale et cognitive, utilisée en complémentarité avec un sevrage médicamenteux graduel, favorise la cessation des benzodiazépi-nes auprès de patients ayant un diagnostic de trouble panique (Otto et al, 1993 ;Spiegel et al, 1994) et d'insomnie (Baillargeon et al, 1998 ;Morin et al, 1995). Ce type d'intervention diminuerait le taux de rechute et favoriserait l'abstinence à long terme (Bruce et al, 1999).…”

Section: E Trouble D'anxiété Généralisée (Tag) Constitue Un Des Trounclassified

Sevrage des benzodiazépines chez des patients souffrant du Trouble d’anxiété généralisée : efficacité d’une intervention comportementale et cognitive

Patrick

Ladouceur

Morin

et al. 2004

smq

Self Cite

View full text Add to dashboard Cite

Résumé Les benzodiazépines sont souvent prescrites pour le traitement à court terme du Trouble d’anxiété généralisée (TAG). La nature chronique du TAG entraîne une prise prolongée de ces psychotropes sur plusieurs mois et plusieurs années, entraînant ainsi une dépendance psychologique et physique. La présente étude vise à déterminer si la combinaison d’une thérapie comportementale et cognitive et d’un sevrage médicamenteux graduel facilite l’arrêt des benzodiazépines chez les patients souffrant d’un TAG. Au total, cinq participants ont reçu l’intervention combinée selon un protocole expérimental à cas uniques avec niveaux de base multiples. Quatre d’entre eux ont complété le plan de sevrage et ont démontré des améliorations cliniques importantes. Les données recueillies lors des suivis 3 et 6 mois indiquent un maintien des gains thérapeutiques. Ces résultats suggèrent que la thérapie comportementale et cognitive facilite l’arrêt des benzodiazépines chez les patients présentant un TAG tout en diminuant significativement les symptômes anxieux.

show abstract

“…Long term follow-up data suggests that treatment gains are well maintained or even enhanced over time. Some evidence also indicates that cognitive-behavior interventions may facilitate the reduction of hypnotic use [23,Class I]. Studies have also shown that patients have a greater acceptance and are more satisfied with behavior interventions, and that treatment gains are more durable than with pharmacotherapy [24, Class II; 25•, Class I].…”

Section: • Psychologic and Behavior Factors Play A Major Role In Perpmentioning

confidence: 99%

Insomnia in adults

Morin

Daley

Ouellet

2001

Curr Treat Options Neurol

Self Cite

View full text Add to dashboard Cite

Insomnia is a prevalent condition, existing as both a symptom and a syndrome, and is associated with significant impairments of daytime functioning, reduced quality of life, and increased risk of depression. When insomnia is secondary to a psychiatric, medical, or another sleep disorder, treatment should focus initially on the underlying condition. For acute and situational insomnia, treatment should address the precipitating factors when possible, but in certain circumstances (eg, stressful events, travel, or jet lag), a hypnotic medication is necessary to alleviate sleep difficulties. Benzodiazepine-receptor agents are the treatment of choice among the pharmacologic options. For chronic and primary insomnia, behavior treatment should represent the main intervention, with hypnotic medications serving as an adjunct. Behavior and pharmacologic treatments can be effectively combined in order to take advantage of the faster results obtained from medication administration, and the longer-lasting benefits associated with behavior interventions. For recurrent insomnia, the use of intermittent medication can be very useful to prevent or minimize continued sleep difficulties.

show abstract

Cognitive behavior therapy to facilitate benzodiazepine discontinuation among hypnotic-dependent patients with insomnia

Cited by 44 publications

References 17 publications

Psychological treatment for insomnia in the regulation of long-term hypnotic drug use

Psychological treatment for insomnia in the regulation of long-term hypnotic drug use

Sevrage des benzodiazépines chez des patients souffrant du Trouble d’anxiété généralisée : efficacité d’une intervention comportementale et cognitive

Insomnia in adults

Contact Info

Product

Resources

About